Innovent’s Sycume to transform thyroid eye disease treatment landscape in China and Asia: GlobalData
Sycume becomes China’s first approved IGF-1R monoclonal antibody for thyroid eye disease, offering a new treatment option after…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Innovent Biologics
Mankind Pharma and Innovent Biologics partner to license and commercialise Sintilimab
Sintilimab, marketed as TYVY (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody…
Dupert offers new hope for advanced NSCLC patients as China’s first KRAS G12C Inhibitor: GlobalData
GlobalData highlights Dupert’s role in addressing the growing KRAS G12C mutation burden in China’s advanced NSCLC treatment…
China’s Innovent holds potential to change pancreatic cancer treatment with bispecific antibody…
Preliminary results from the Phase I study demonstrated promising efficacy in pancreatic ductal adenocarcinoma and the bispecific…
Innovent Biologics mazdutide can pave way for transformative T2D treatment: GlobalData
Mazdutide will be the second drug from Innovent Biologics in Chinese metabolic disorders market
China’s Innovent Biologics secures over $300 million investment from Sanofi
The all-cash investment by Sanofi unit Sanofi Foreign Participations BV will be at a price of $42.42 per Innovent share,…
US FDA grants Orphan Drug Designation to BCMA CAR-T cell therapy co-developed by Innovent Biologics…
ODD will accelerate drug development and registration action in the US
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of…
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…